J. Goldman & Co’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

J. Goldman & Co’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-94,500	Closed	-$3.56M	–	598
2021 Q1	$3.56M	Buy	+94,500	New	+$2.36M	0.11%	192

J. Goldman & Co's FPRX Position: Q2 2021 in Review

J. Goldman & Co sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 6,187 shares — an estimated $233K sold.

J. Goldman & Co first reported a position in FPRX in Q2 2015 and held it in 3 quarters. The position peaked at $4.83M in Q3 2015. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

J. Goldman & Co reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
J. Goldman & Co sold 6,187 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $233K.
J. Goldman & Co first reported a position in Five Prime Therapeutics, Inc. in Q2 2015 and held it in 3 quarters.
J. Goldman & Co's Five Prime Therapeutics, Inc. position peaked at $4.83M in Q3 2015.
0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on J. Goldman & Co's 13F filing for Q2 2021, filed 16 Aug 2021.